Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - cobicistat, quantity: 150 mg; atazanavir, quantity: 300 mg - tablet, film coated - excipient ingredients: stearic acid; croscarmellose sodium; hyprolose; crospovidone; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide red - evotaz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: crospovidone; sodium stearylfumarate; lactose; povidone; microcrystalline cellulose - hypertension: monopril is indicated in the treatment of mild to moderate hypertension. monopril is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monopril in severe or renovascular hypertension. heart failure: monopril is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - deucravacitinib, quantity: 6 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose acetate succinate; microcrystalline cellulose; silicon dioxide; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sotyktu is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - aztreonam, quantity: 1 g - injection, powder for - excipient ingredients: arginine - indications as at 23 may 1991: 1. azactam is indicated for use as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc. 2. in combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an aminoglycoside because of synergistic action. however, this enhanced activity is not predictable. if such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be u

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: sucrose; water for injections; monobasic sodium phosphate; poloxamer; nitrogen; dibasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 125.875 mg - injection - excipient ingredients: dibasic sodium phosphate; nitrogen; water for injections; sucrose; poloxamer; monobasic sodium phosphate - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 341.69 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - abatacept, quantity: 262.5 mg - injection - excipient ingredients: monobasic sodium phosphate; sodium chloride; sodium hydroxide; maltose; hydrochloric acid - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate.,orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.,orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used as monotherapy or concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.),orencia is indicated for the treatment of active psoriatic arthritis (psa) in adults when the response to previous disease-modifying anti-rheumatic drug (dmard) therapy has been inadequate. orencia can be used with or without non-biologic dmards.,orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).